{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:17:35Z","timestamp":1788499055282,"version":"build-2803163510"},"reference-count":222,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Despite major advances in lipid-lowering therapies, a significant unmet need remains, particularly for patients with homozygous familial hypercholesterolemia (HoFH), severe heterozygous familial hypercholesterolemia (HeFH), and those who fail to achieve guideline-recommended LDL-C targets. Nucleic acid-based therapeutics have emerged as a transformative approach for treating hypercholesterolemia. Antisense oligonucleotides and small interfering RNAs (siRNAs) have demonstrated durable hepatic gene silencing and have led to approved therapies, while gene replacement and in vivo genome-editing strategies offer the potential for long-lasting, and possibly one-time, interventions. In parallel, microRNAs (miRNAs) have attracted increasing interest because of their ability to coordinately regulate multiple genes involved in lipoprotein metabolism, cholesterol transport, and lipid homeostasis. Human genetic studies further support the importance of miRNA-mediated regulation, exemplified by a rare ~2.5 kb deletion in the distal LDLR 3\u2032UTR (\u201cdel2.5\u201d) that disrupts miRNA-binding sites and is associated with lifelong low LDL-C levels. This review summarizes recent advances, mechanisms of action, clinical progress, and remaining challenges across antisense oligonucleotides, siRNAs, gene therapy, genome editing, and emerging miRNA-based therapeutics for hypercholesterolemia. As an example of the latter approach, the liver-directed miR-30c analog C2 has demonstrated preclinical activity by coordinately reducing hepatic lipoprotein secretion and lipogenesis while enhancing cholesterol elimination, resulting in reduced LDL-C and atherosclerosis. However, it must be noted that these findings remain preclinical, and further optimization of delivery, pharmacokinetics, safety, and long-term efficacy will be required before clinical evaluation. Continued advances in RNA chemistry, targeted delivery, and genome engineering are expected to further expand the therapeutic landscape for dyslipidemia and cardiovascular disease.<\/jats:p>","DOI":"10.3390\/cells15171575","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Nucleic Acid-Based Therapies for Hypercholesterolemia with Focus on a New Modality, Liver-Directed miR-30c Analog C2"],"prefix":"10.3390","volume":"15","author":[{"given":"Rai Ajit K.","family":"Srivastava","sequence":"first","affiliation":[{"name":"Mirnacures Therapeutics Inc., Boston, MA 02101-02117, USA"},{"name":"NYU Grossman School of Medicine, NYU Langone (Long Island), Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists Collaboration, Fulcher, J., O\u2019Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., Simes, J., Collins, R., and Kirby, A. (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 385, 1397\u20131405.","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0025-7125(16)31424-9","article-title":"The LDL receptor defect in familial hypercholesterolemia: Implications for pathogenesis and therapy","volume":"66","author":"Goldstein","year":"1982","journal-title":"Med. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2217\/pgs.15.113","article-title":"Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment","volume":"16","author":"Santos","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11886-017-0848-8","article-title":"Genetic Architecture of Familial Hypercholesterolaemia","volume":"19","author":"Sharifi","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2005.08.015","article-title":"Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia","volume":"186","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2021.08.024","article-title":"Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry","volume":"333","author":"Desperak","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_10","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Srivastava, R.A.K. (2023). A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD. Cells, 12.","DOI":"10.3390\/cells12121648"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.numecd.2023.08.010","article-title":"New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome\/base editing","volume":"33","author":"Srivastava","year":"2023","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance\u2014An attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients with Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.3283935","article-title":"Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology","volume":"240","author":"Mahley","year":"1988","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-3233(08)60642-7","article-title":"Apolipoprotein E: Structure-function relationships","volume":"45","author":"Weisgraber","year":"1994","journal-title":"Adv. Protein. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/hep.25580","article-title":"Inhibition of hepatic sulfatase-2 in vivo: A novel strategy to correct diabetic dyslipidemia","volume":"55","author":"Hassing","year":"2012","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"G333","DOI":"10.1152\/ajpgi.00150.2019","article-title":"Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease","volume":"319","author":"Kim","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of Statin in Routine Care Settings: A Cohort Study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of Prior Authorization and Out-of-pocket Costs with Patient Access to PCSK9 Inhibitor Therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated Cost-effectiveness Assessments of PCSK9 Inhibitors from the Perspectives of the Health System and Private Payers: Insights Derived from the FOURIER Trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22713","article-title":"PCSK9 inhibitor access barriers\u2014Issues and recommendations: Improving the access process for patients, clinicians and payers","volume":"40","author":"Baum","year":"2017","journal-title":"Clin. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e003939","DOI":"10.1161\/CIRCOUTCOMES.117.003939","article-title":"Prior Authorization Requirements for Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors across US Private and Public Payers","volume":"11","author":"Doshi","year":"2018","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e040768","DOI":"10.1161\/JAHA.125.040768","article-title":"Prescriber Uptake and Use of Novel Lipid-Lowering Therapies","volume":"14","author":"Hwang","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.tem.2010.08.008","article-title":"MicroRNAs and cholesterol metabolism","volume":"21","author":"Moore","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/ATVBAHA.112.300144","article-title":"MicroRNAs in metabolic disease","volume":"33","author":"Goedeke","year":"2013","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1194\/jlr.M081299","article-title":"microRNA-30c reduces plasma cholesterol in homozygous familial hypercholesterolemic and type 2 diabetic mouse models","volume":"59","author":"Irani","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm.3949","article-title":"MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels","volume":"21","author":"Goedeke","year":"2015","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e003029","DOI":"10.1161\/CIRCGEN.120.003029","article-title":"Lifelong Reduction in LDL (Low-Density Lipoprotein) Cholesterol due to a Gain-of-Function Mutation in LDLR","volume":"14","author":"Bjornsson","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nm.3200","article-title":"MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion","volume":"19","author":"Soh","year":"2013","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"18397","DOI":"10.1074\/jbc.M116.728451","article-title":"MicroRNA-30c Mimic Mitigates Hypercholesterolemia and Atherosclerosis in Mice","volume":"291","author":"Irani","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","article-title":"Statin-Associated Muscle Disease: Advances in Diagnosis and Management","volume":"15","author":"Taylor","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: A new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","article-title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program","volume":"278","author":"Farnier","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature09267","article-title":"Mammalian microRNAs predominantly act to decrease target mRNA levels","volume":"466","author":"Guo","year":"2010","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: From cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of dna-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein b, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"JACC"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"McGowan, M.P., Tardif, J.-C., Ceska, R., Burgess, L.J., Soran, H., Gouni-Berthold, I., Wagener, G., and Chasan-Taber, S. (2012). Randomized, Placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049006"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCRESAHA.113.302732","article-title":"Small RNA overcomes the challenges of therapeutic targeting of microsomal triglyceride transfer protein","volume":"113","author":"Vickers","year":"2013","journal-title":"Circ. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/35005107","article-title":"An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells","volume":"404","author":"Hammond","year":"2000","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/418244a","article-title":"RNA interference","volume":"418","author":"Hannon","year":"2002","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: Advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: The ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11883-024-01254-y","article-title":"Inhibition of the ANGPTL3\/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease","volume":"27","author":"Chan","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-025-01295-x","article-title":"Novel Therapeutics for Familial Chylomicronemia Syndrome","volume":"27","author":"Izar","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.90.7.2812","article-title":"Adenovirus-mediated transfer of low-density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice","volume":"90","author":"Herz","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-2254(200001\/02)2:1<41::AID-JGM79>3.0.CO;2-P","article-title":"Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade","volume":"2","author":"Stein","year":"2000","journal-title":"J. Gene Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0021-9258(18)48379-2","article-title":"Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits","volume":"267","author":"Wilson","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.1722351","article-title":"Long-term improvement of hypercholesterolemia after ex vivo gene therapy in ldlr-deficient rabbits","volume":"254","author":"Chowdhury","year":"1991","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jgm.554","article-title":"Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia","volume":"6","author":"Lebherz","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.atherosclerosis.2006.08.056","article-title":"Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits","volume":"193","author":"Kitajima","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/1074-7613(94)90074-4","article-title":"MHC class I-cestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses","volume":"1","author":"Yang","year":"1994","journal-title":"Immunity"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1172\/JCI117725","article-title":"In vivo gene therapy for hyperlipidemia: Phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene","volume":"95","author":"Li","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/humc.2017.014","article-title":"Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR +\/\u2212 Rhesus Macaques","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1089\/hum.2024.164","article-title":"AAV8- LDLR Gene Therapy in Ldlr -KO and Homozygous Ldlr p.W483X Mice","volume":"36","author":"Li","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Calcedo, R., and Wilson, J.M. (2013). Humoral Immune Response to AAV. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00341"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Hamilton, B.A., and Wright, J.F. (2021). Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.675897"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/CIRCRESAHA.115.304008","article-title":"AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia","volume":"115","author":"Somanathan","year":"2014","journal-title":"Circ. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0014-5793(80)81223-3","article-title":"WHHL-rabbit: A low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia","volume":"118","author":"Tanzawa","year":"1980","journal-title":"FEBS Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1073\/pnas.78.4.2268","article-title":"Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia","volume":"78","author":"Kita","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1073\/pnas.79.10.3305","article-title":"Impaired receptor-mediated catabolism of low density lipoprotein in the WHHL rabbit, an animal model of familial hypercholesterolemia","volume":"79","author":"Bilheimer","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","first-page":"797","article-title":"Watanabe rabbits with heritable hypercholesterolaemia: A model of atherosclerosis","volume":"13","author":"Aliev","year":"1998","journal-title":"Histol. Histopathol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"406473","DOI":"10.1155\/2011\/406473","article-title":"Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases","volume":"2011","author":"Kobayashi","year":"2011","journal-title":"BioMed Res. Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2013.08.030","article-title":"Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins","volume":"231","author":"Shiomi","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5551\/jat.RV17038-1","article-title":"The History of the WHHL Rabbit, an Animal Model of Familial Hypercholesterolemia (I)\u2014Contribution to the Elucidation of the Pathophysiology of Human Hypercholesterolemia and Coronary Heart Disease","volume":"27","author":"Shiomi","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1073\/pnas.85.12.4421","article-title":"Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit","volume":"85","author":"Wilson","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/hum.1992.3.2-179","article-title":"Ex vivo gene therapy of familial hypercholesterolemia","volume":"3","author":"Wilson","year":"1992","journal-title":"Hum. Gene Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1752-8062.2010.00190.x","article-title":"Comparative cardiac gene delivery of adeno-associated virus serotypes 1\u20139 reveals that aav6 mediates the most efficient transduction in mouse heart","volume":"3","author":"Zincarelli","year":"2010","journal-title":"Clin. Transl. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-61779-370-7_6","article-title":"AAV-mediated liver-directed gene therapy","volume":"807","author":"Sands","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-4939-9065-8_12","article-title":"AAV-Mediated Gene Delivery to the Mouse Liver","volume":"1937","author":"Cunningham","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.omtm.2021.11.011","article-title":"Novel human liver-tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8","volume":"24","author":"Navarro","year":"2022","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2004.01.015","article-title":"Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy","volume":"9","author":"Kankkonen","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_114","unstructured":"NHLB (National Heart, L., and Blood Institute) (2026, August 25). A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02651675."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/humc.2013.082","article-title":"Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia","volume":"24","author":"Chen","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/humc.2017.007","article-title":"Nonclinical Pharmacology\/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","article-title":"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery","volume":"92","author":"Ishibashi","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1073\/pnas.91.10.4431","article-title":"The two-receptor model of lipoprotein clearance: Tests of the hypothesis in \u201cknockout\u201d mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins","volume":"91","author":"Ishibashi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Kassim, S.H., Li, H., Vandenberghe, L.H., Hinderer, C., Bell, P., Marchadier, D., Wilson, A., Cromley, D., Redon, V., and Yu, H. (2010). Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013424"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/sj.gt.3302819","article-title":"Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector","volume":"14","author":"Oka","year":"2007","journal-title":"Gene Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"13695","DOI":"10.1016\/S0021-9258(17)36886-2","article-title":"In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses","volume":"269","author":"Kozarsky","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Simoni, C., Barbon, E., Muro, A.F., and Cantore, A. (2024). Andr In vivo liver targeted genome editing as therapeutic approach: Progresses and challenges. Front. Genome Ed., 6.","DOI":"10.3389\/fgeed.2024.1458037"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Kantor, A., McClements, M.E., and MacLaren, R.E. (2020). CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176240"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nmeth.2649","article-title":"Cas9 as a versatile tool for engineering biology","volume":"10","author":"Mali","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.ymthe.2025.03.026","article-title":"Recent advances in therapeutic gene-editing technologies","volume":"33","author":"Liu","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1042\/BCJ20170793","article-title":"CRISPR base editors: Genome editing without double-stranded breaks","volume":"475","author":"Eid","year":"2018","journal-title":"Biochem. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41596-020-00450-9","article-title":"Precision genome editing using cytosine and adenine base editors in mammalian cells","volume":"16","author":"Huang","year":"2021","journal-title":"Nat. Protoc."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11684-023-1013-y","article-title":"Base editors: Development and applications in biomedicine","volume":"17","author":"Liang","year":"2023","journal-title":"Front. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibtech.2025.07.012","article-title":"Third-generation novel technologies for gene editing","volume":"44","author":"Gupta","year":"2026","journal-title":"Trends Biotechnol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1021\/acs.accounts.1c00500","article-title":"Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing","volume":"54","author":"Qiu","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"100450","DOI":"10.1016\/j.dmpk.2022.100450","article-title":"Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics","volume":"44","author":"Mukai","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Swetha, K., Kotla, N.G., Tunki, L., Jayaraj, A., Bhargava, S.K., Hu, H., Bonam, S.R., and Kurapati, R. (2023). Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines, 11.","DOI":"10.20944\/preprints202302.0142.v1"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"115461","DOI":"10.1016\/j.addr.2024.115461","article-title":"Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids","volume":"215","author":"Bader","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/ATVBAHA.117.309326","article-title":"CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia","volume":"38","author":"Chadwick","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kaupbayeva, B., Tsoy, A., Safarova, Y., Nurmagambetova, A., Murata, H., Matyjaszewski, K., and Askarova, S. (2024). Unlocking Genome Editing: Advances and Obstacles in CRISPR\/Cas Delivery Technologies. J. Funct. Biomater., 15.","DOI":"10.3390\/jfb15110324"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12951-025-03895-w","article-title":"Nanomaterials in gene therapy and genome editing: Challenges and emerging directions","volume":"24","author":"Jiang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e01475","DOI":"10.1002\/adhm.202501475","article-title":"Co-Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR-T Cells","volume":"15","author":"Wang","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/978-1-0716-1924-7_42","article-title":"In Vivo Gene Editing in Lipid and Atherosclerosis Research","volume":"2419","author":"Jarrett","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In Vivo AAV-CRISPR\/Cas9\u2013Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/ATVBAHA.117.309881","article-title":"In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) as a Therapeutic Alternative to Genome Editing","volume":"37","author":"Chadwick","year":"2017","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo\u2014Brief Report","volume":"36","author":"Wang","year":"2016","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"ref_151","unstructured":"Verve Therapeutics, Inc. (2026, August 25). A Study of VERVE-101 in Patients with Familial Hypercholesterolemia and Cardiovascular Disease. ClinicalTrials.gov 2025, NCT05398029, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05398029."},{"key":"ref_152","unstructured":"Verve Therapeutics, Inc. (2026, August 25). A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease. ClinicalTri-als.gov 2026. NCT06164730, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06164730."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/hum.2022.090","article-title":"Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies","volume":"33","author":"Moffit","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41591-026-04254-4","article-title":"In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: A phase 1 trial","volume":"32","author":"Wan","year":"2026","journal-title":"Nat. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41591-026-04220-0","article-title":"Base editing milestone for familial hypercholesterolemia","volume":"32","author":"Rosenson","year":"2026","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 Deficiency and Protection Against Coronary Artery Disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","article-title":"Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk","volume":"45","author":"Gobeil","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: Phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"102486","DOI":"10.1016\/j.omtn.2025.102486","article-title":"In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease","volume":"36","author":"Khirallah","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_161","unstructured":"Therapeutics, C. (2026, August 25). A Safety and Tolerability Trial Evaluating CTX310 in Participants with Refractory Dyslipidemias. ClinicalTrials.gov, 2026. NCT07491172, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07491172."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/s41467-020-17889-9","article-title":"Genome-wide specificity of dCpf1 cytidine base editors","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ehjcvp\/pvad095","article-title":"First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: A new frontier in cardiovascular pharmacotherapy? News from AHA","volume":"10","author":"Lewis","year":"2024","journal-title":"Eur. Heart J.\u2014Cardiovasc. Pharmacother."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1093\/cvr\/cvae037","article-title":"First-in-human gene editing for lipid lowering: The initial results","volume":"120","author":"Stellos","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., and Chen, Y.E. (2026). Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress. Cells, 15.","DOI":"10.3390\/cells15020134"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMoa2510209","article-title":"Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy","volume":"393","author":"Gillmore","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/35002607","article-title":"The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans","volume":"403","author":"Reinhart","year":"2000","journal-title":"Nature"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.1064921","article-title":"Identification of novel genes coding for small expressed RNAs","volume":"294","author":"Rauhut","year":"2001","journal-title":"Science"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1065062","article-title":"An abundant class of tiny rnas with probable regulatory roles in Caenorhabditis elegans","volume":"294","author":"Lau","year":"2001","journal-title":"Science"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Lee","year":"2003","journal-title":"Nature"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.molcel.2007.05.001","article-title":"Argonaute Proteins: Mediators of RNA Silencing","volume":"26","author":"Peters","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature07228","article-title":"Widespread changes in protein synthesis induced by microRNAs","volume":"455","author":"Selbach","year":"2008","journal-title":"Nature"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1126\/science.1189862","article-title":"MiR-33 contributes to the regulation of cholesterol homeostasis","volume":"328","author":"Rayner","year":"2010","journal-title":"Science"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1126\/science.1189123","article-title":"MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis","volume":"328","author":"Kristo","year":"2010","journal-title":"Science"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1038\/ncomms3883","article-title":"MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice","volume":"4","author":"Horie","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature10486","article-title":"Inhibition of miR-33a\/b in non-human primates raises plasma HDL and lowers VLDL triglycerides","volume":"478","author":"Rayner","year":"2011","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/ATVBAHA.113.301732","article-title":"Therapeutic silencing of MicroRNA-33 inhibits the progression of atherosclerosis in Ldlr\u00a0\u2212\/\u2212 Mice\u2014Brief report","volume":"33","author":"Rotllan","year":"2013","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-319-22380-3_5","article-title":"Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis","volume":"887","author":"Santulli","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/CIRCRESAHA.112.300648","article-title":"MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor","volume":"112","author":"Vallim","year":"2013","journal-title":"Circ. Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.drudis.2022.05.003","article-title":"Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic diseases and development of novel therapeutics","volume":"27","author":"Khan","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"112929","DOI":"10.1016\/j.exger.2025.112929","article-title":"Expression analysis of miR-93, miR-122, and miR-192 in patients with coronary artery disease","volume":"211","author":"Sohrabifar","year":"2025","journal-title":"Exp. Gerontol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u2018antagomirs\u2019","volume":"438","author":"Rajewsky","year":"2005","journal-title":"Nature"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"101813","DOI":"10.1016\/j.jbc.2022.101813","article-title":"Novel efficacious microRNA-30c analogs reduce apolipoprotein B secretion in human hepatoma and primary hepatocyte cells","volume":"298","author":"Yadav","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.3980","article-title":"Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis","volume":"21","author":"Wagschal","year":"2015","journal-title":"Nat. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00018-011-0857-5","article-title":"Regulation of cholesterol homeostasis","volume":"69","author":"Goedeke","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"847849","DOI":"10.1155\/2012\/847849","article-title":"MicroRNA Regulation of Cholesterol Metabolism","volume":"2012","author":"Rotllan","year":"2012","journal-title":"Cholesterol"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH11-10-0694","article-title":"MicroRNAs regulating lipid metabolism in atherogenesis","volume":"107","author":"Rayner","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_193","first-page":"466","article-title":"CRISPR-based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia","volume":"30","author":"Lev","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_194","first-page":"8","article-title":"Familial hypercholesterolemia: Pathogenesis of a receptor disease","volume":"143","author":"Goldstein","year":"1978","journal-title":"Johns Hopkins Med. J."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"A4363116","DOI":"10.1161\/circ.152.suppl_3.4363116","article-title":"Hepatic Delivery of Micro RNA-30C Analog C2 Reduces Plasma Cholesterol in Mice and Monkeys and Atherosclerosis in Mice Without Causing Liver Injury","volume":"152","author":"Prakash","year":"2025","journal-title":"Circulation"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1038\/s41598-024-54092-y","article-title":"miR-30c affects the pathogenesis of ulcerative colitis by regulating target gene VIP","volume":"14","author":"Dong","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1038\/emm.2016.57","article-title":"miR-30c regulates proliferation, apoptosis and differentiation via the Shh signaling pathway in P19 cells","volume":"48","author":"Liu","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/cvr\/cvx157","article-title":"miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways","volume":"113","author":"Ceolotto","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13287-020-02127-2","article-title":"MiR-30c-5p regulates adventitial progenitor cells differentiation to vascular smooth muscle cells through targeting OPG","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1111\/jcmm.15764","article-title":"Long non-coding RNA CASC7 is associated with the pathogenesis of heart failure via modulating the expression of miR-30c","volume":"24","author":"Xu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1172\/JCI123106","article-title":"Endothelial miR-30c suppresses tumor growth via inhibition of TGF-\u03b2\u2013induced Serpine1","volume":"129","author":"McCann","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_204","first-page":"169","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Cardiol. Clin."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Dybiec, J., Baran, W., D\u0105bek, B., Fularski, P., M\u0142ynarska, E., Radzioch, E., and Franczyk, B. (2023). Advances in Treatment of Dyslipidemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713288"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K.K.-W., and Shi, C. (2021). MicroRNA as an Important Target for Anticancer Drug Development. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.736323"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Reda El Sayed, S., Cristante, J., Guyon, L., Denis, J., Chabre, O., and Cherradi, N. (2021). MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers, 13.","DOI":"10.3390\/cancers13112680"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Desantis, V., Saltarella, I., Lamanuzzi, A., Melaccio, A., Solimando, A.G., Mariggi\u00f2, M.A., Racanelli, V., Paradiso, A., Vacca, A., and Frassanito, M.A. (2020). MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093084"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12263-017-0577-z","article-title":"Role of microRNAs in obesity and obesity-related diseases","volume":"12","author":"Iacomino","year":"2017","journal-title":"Genes Nutr."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/msb.2011.100","article-title":"Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer","volume":"8","author":"Uhlmann","year":"2012","journal-title":"Mol. Syst. Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","article-title":"Regulation of microRNA function in animals","volume":"20","author":"Gebert","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Raue, R., Frank, A.-C., Syed, S.N., and Br\u00fcne, B. (2021). Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042210"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.molcel.2010.11.038","article-title":"The miR-17-92 MicroRNA cluster regulates multiple components of the TGF-\u03b2 pathway in neuroblastoma","volume":"40","author":"Mestdagh","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_215","first-page":"4607","article-title":"Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis","volume":"11","author":"Borsuk","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Hanna, J., Hossain, G.S., and Kocerha, J. (2019). The Potential for microRNA Therapeutics and Clinical Research. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00478"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/s41467-026-72276-0","article-title":"MicroRNA-30c analog C2 decreases plasma cholesterol and atherosclerosis without causing liver injury in preclinical studies","volume":"17","author":"Prakash","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Prakash, B., Chang, Z., Rajan, S., Scarberry, S.R., Gangula, B., Hossain, M.M., and Hussain, M.M. (2026). MicroRNA-30c analog C2 additively reduces plasma cholesterol and apoB, and atherosclerosis with atorvastatin and ezitimibe in Western diet fed female ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol., 46.","DOI":"10.1161\/atvb.46.suppl_1.Fri017"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.bbalip.2016.02.020","article-title":"MicroRNAs regulating apolipoprotein B-containing lipoprotein production","volume":"1861","author":"Zhou","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Seyhan, A.A. (2024). Trials and Tribulations of MicroRNA Therapeutics. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031469"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:34:17Z","timestamp":1788496457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":222,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15171575"],"URL":"https:\/\/doi.org\/10.3390\/cells15171575","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}